Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca    AZN   GB0009895292

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

AstraZeneca : Researchers at AstraZeneca Report Findings in Chemical Biology (Identification and Characterization of Dual Inhibitors of the USP25/28...

share with twitter share with LinkedIn share with facebook
share via e-mail
12/07/2017 | 11:57pm CET

Researchers at AstraZeneca Report Findings in Chemical Biology (Identification and Characterization of Dual Inhibitors of the USP25/28 Deubiquitinating Enzyme Subfamily)

By a News Reporter-Staff News Editor at Cancer Weekly -- Research findings on Life Science Research - Chemical Biology are discussed in a new report. According to news reporting originating from Cambridge, United Kingdom, by NewsRx correspondents, research stated, "The ubiquitin proteasome system is widely postulated to be a new and important field of drug discovery for the future, with the ubiquitin specific proteases (USPs) representing one of the more attractive target classes within the area. Many USPs have been linked to critical axes for therapeutic intervention, and the finding that USP28 is required for c-Myc stability suggests that USP28 inhibition may represent a novel approach to targeting this so far undruggable oncogene."

Our news editors obtained a quote from the research from AstraZeneca, "Here, we describe the discovery of the first reported inhibitors of USP28, which we demonstrate are able to bind to and inhibit USP28, and while displaying a dual activity against the closest homologue USP25, these inhibitors show a high degree of selectivity over other deubiquitinases (DUBs). The utility of these compounds as valuable probes to investigate and further explore cellular DUB biology is highlighted by the demonstration of target engagement against both USP25 and USP28 in cells. Furthermore, we demonstrate that these inhibitors are able to elicit modulation of both the total levels and the half-life of the c-Myc oncoprotein in cells and also induce apoptosis and loss of cell viability in a range of cancer cell lines. We however observed a narrow therapeutic index compared to a panel of tissue-matched normal cell lines."

According to the news editors, the research concluded: "Thus, it is hoped that these probes and data presented herein will further advance our understanding of the biology and tractability of DUBs as potential future therapeutic targets."

For more information on this research see: Identification and Characterization of Dual Inhibitors of the USP25/28 Deubiquitinating Enzyme Subfamily. Acs Chemical Biology, 2017;():. (American Chemical Society - www.acs.org; Acs Chemical Biology - www.pubs.acs.org/journal/acbcct)

The news editors report that additional information may be obtained by contacting J.D. Wrigley, Discovery Sciences, IMED Biotech Unit, AstraZeneca , Cambridge, UK. Additional authors for this research include G. Gavory, I. Simpson, M. Preston, H. Plant, J. Bradley, A.U. Goeppert, E. Rozycka, G. Davies, J. Walsh, A. Valentine, K. McClelland, K.E. Odrzywol, J. Renshaw, J. Boros, J. Tart, L. Leach, T. Nowak and R Ward (see also Life Science Research - Chemical Biology).

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1021/acschembio.7b00334. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

Keywords for this news article include: Europe, Cambridge, United Kingdom, Chemical Biology, Drugs and Therapies, Life Science Research.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ASTRAZENECA
07:03a Merck raises stakes in lung cancer as rivals close in
12/10 ASTRAZENECA : ’s CALQUENCE® (acalabrutinib) Shows Potential in Chronic Lym..
12/09 ASTRAZENECA : ’s CALQUENCE® (acalabrutinib) Demonstrates Activity in Relap..
12/08 ASTRAZENECA : to highlight its commitment to blood cancers at the 2017 American ..
12/07 ASTRAZENECA : Researchers at AstraZeneca Report Findings in Chemical Biology (Id..
12/07 ASTRAZENECA : Reports on Non-Small Cell Lung Cancer Findings from AstraZeneca Pr..
12/07 ASTRAZENECA : Reports from AstraZeneca Describe Recent Advances in Capsaicin (XE..
12/07 ASTRAZENECA : Drugmakers line up to invest in UK life sciences
12/07 U.K. unveils life sciences sector deal
More news
News from SeekingAlpha
12/09 3 THINGS IN BIOTECH YOU SHOULD LEARN : December 9, 2017
12/07 Pieris on go with early-stage study of inhaled therapy for treatment-resistan..
12/07 TESARO : Updates To Thesis
12/06 CLOVIS ONCOLOGY : 2018 Turnaround Story
12/06 BIOTECH ANALYSIS CENTRAL PHARMA NEWS : Galectin's Failure, Revance's Positive Re..
Financials ($)
Sales 2017 21 817 M
EBIT 2017 5 884 M
Net income 2017 2 293 M
Debt 2017 12 395 M
Yield 2017 4,26%
P/E ratio 2017 32,28
P/E ratio 2018 27,25
EV / Sales 2017 4,28x
EV / Sales 2018 4,28x
Capitalization 81 090 M
Duration : Period :
AstraZeneca Technical Analysis Chart | AZN | GB0009895292 | 4-Traders
Technical analysis trends ASTRAZENECA
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 34
Average target price 68,3 $
Spread / Average Target 6,6%
EPS Revisions
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Dunoyer Chief Financial Officer & Executive Director
Sean Bohen Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA6.41%81 598
JOHNSON & JOHNSON21.23%377 698
NOVARTIS11.34%218 728
PFIZER9.48%213 036
ROCHE HOLDING LTD.6.19%208 877
MERCK AND COMPANY-7.68%151 559